Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Andersson, Emilia ^a   Poschke, Isabel ^a,b   Villabona, Lisa ^a   Carlson, Joseph W ^a   Lundqvist, Andreas ^a   Kiessling, Rolf ^a   Seliger, Barbara ^c   Masucci, Giuseppe V ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

HLA A*02; HLA E; HLA G; Immunohistochemistry; Ovarian cancer; Prognosis; Serous adenocarcinoma

Indexed keywords

HLA ANTIGEN CLASS 1; HLA E ANTIGEN; HLA G ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR FOXP3;

ADENOCARCINOMA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASCITES FLUID; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA EXTRACTION; FEMALE; FLOW CYTOMETRY; GENETIC ANALYSIS; GENOTYPE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; TUMOR MICROENVIRONMENT;

EID: 84954457400     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1052213     Document Type: Article

References (56)

1. Anderson ARA, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006; 127:905-15; PMID:17129778; http://dx. doi. org/10. 1016/j. cell. 2006. 09. 042
2. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329-60; PMID:15032581; http://dx. doi. org/ 10. 1146/annurev. immunol. 22. 012703. 104803
3. Swartz MA, Lund AW. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer 2012; 12:210-9; PMID:22362216; http://dx. doi. org/10. 1038/nrc3186
4. Serrano A, Castro-Vega I, Redondo M. Role of gene methylation in antitumor immune response: implication for tumor progression. Cancers 2011; 3:1672-90; PMID:24212778; http://dx. doi. org/10. 3390/cancers 3021672
5. Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol 2011; 2011:14; http://dx. doi. org/10. 1155/ 2011/430394
6. Paschen A, Méndez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003; 103:759-67; http://dx. doi. org/ 10. 1002/ijc. 10906
7. Campoli M, Ferrone S. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 2008; 72:321-34; PMID:18700879; http://dx. doi. org/10. 1111/j. 1399-0039. 2008. 01106. x
8. Browning M, Dunnion D. HLA and cancer: implications for cancer immunotherapy and vaccination. Eur J Immunogenet 1997; 24:293-312; PMID:9306099; http://dx. doi. org/10. 1111/j. 1365-2370. 1997. tb00025. x
9. Sioud M. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol 2009; 70:516-25; PMID:19906192; http://dx. doi. org/10. 1111/j. 1365-3083. 2009. 02326. x
10. Garrido F, Cabrera T, Aptsiauri N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010; 127:249-56; PMID:20178101; http://dx. doi. org/10. 1002/ijc. 25270#
11. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008; 57:1719-26; PMID:18408926; http://dx. doi. org/10. 1007/s00262-008-0515-4
12. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90:1-50; PMID:16730260; http://dx. doi. org/10. 1016/S0065-2776(06)90001-7
13. Gamzatova Z, Villabona L, van der Zanden H, Haasnoot GW, Andersson E, Kiessling R, Seliger B, Kanter L, Dalianis T, Bergfeldt K et al. Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. Tissue Antigens 2007; 70:205-13; PMID:17661908; http:// dx. doi. org/10. 1111/j. 1399-0039. 2007. 00875. x
14. Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B et al. The common Scandinavian human leucocyte antigen ancestral haplotype 62. 1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 2009; 58:1599-608; PMID:19214504; http://dx. doi. org/10. 1007/s00262-009-0669-8
15. De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, van der Zanden HG, Masucci G. Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol 2004; 21:49-52; PMID:15034213; http://dx. doi. org/ 10. 1385/MO:21:1:49
16. Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B et al. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res 2006; 66:6387-94; PMID:16778217; http://dx. doi. org/10. 1158/0008-5472. CAN-06-0029
17. Villabona L, Leon Rodriguez DA, Andersson EK, Seliger B, Dalianis T, Masucci GV. A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA. Mod Pathol 2014; 27:1296-305; PMID:24504073; http://dx. doi. org/10. 1038/ modpathol. 2013. 210
18. So T, Takenoyama M, Sugaya M, Yasuda M, Eifuku R, Yoshimatsu T, Osaki T, Yasumoto K. Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 2001; 32:39-46; PMID:11282427; http://dx. doi. org/ 10. 1016/S0169-5002(00)00204-X
19. Rogentine CN, Jr., Dellon AL, Chretien PB. Prolonged disease-free survival in bronchogenic carcinoma associated with HLA-Aw19 and HLA-B5. A two-year prospective study. Cancer 1977; 39:2345-7; PMID:872033; http://dx. doi. org/10. 1002/1097-0142 (197706)39:6%3c2345::AIDCNCR2820390605% 3e3. 0. CO;2-W
20. Tisch M, Kyrberg H, Weidauer H, Mytilineos J, Conradt C, Opelz G, Maier H. Human leukocyte antigens and prognosis in patients with head and neck cancer: results of a prospective follow-up study. Laryngoscope 2002; 112:651-7; PMID:12150518; http://dx. doi. org/ 10. 1097/00005537-200204000-00011
21. Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 2003; 64:315-26; PMID:12590976; http://dx. doi. org/10. 1016/S0198-8859(02)00821-2
22. Rouas-Freiss N, Moreau P, LeMaoult J, Carosella ED. The dual role of HLA-G in cancer. J Immunol Res 2014; 2014:359748; PMID:24800261; http://dx. doi. org/10. 1155/2014/359748
23. Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997; 186:289-98; PMID:9221758; http://dx. doi. org/10. 1084/jem. 186. 2. 289
24. Le DiscordeM, Moreau P, Sabatier P, Legeais JM, Carosella ED. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol 2003; 64:1039-44; PMID:14602233; http://dx. doi. org/ 10. 1016/j. humimm. 2003. 08. 346
25. Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, Torbett BE, Meda P, Crisa L. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes 2006; 55:1214-22; PMID:16644675; http://dx. doi. org/ 10. 2337/db05-0731
26. Menier C, Rabreau M, Challier JC, Le Discorde M, Carosella ED, Rouas-Freiss N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 2004; 104:3153-60; PMID:15284117; http://dx. doi. org/10. 1182/blood-2004-03-0809
27. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003; 81:199-252; PMID:14711057; http://dx. doi. org/10. 1016/S0065-2776(03)81006-4
28. Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella ED. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 2007; 17:413-21; PMID:17881247; http://dx. doi. org/10. 1016/j. semcancer. 2007. 07. 003
29. Riteau B, Faure F, Menier C, Viel S, Carosella ED, Amigorena S, Rouas-Freiss N. Exosomes bearing HLAG are released by melanoma cells. Hum Immunol 2003; 64:1064-72; PMID:14602237; http://dx. doi. org/10. 1016/j. humimm. 2003. 08. 344
30. Kleinberg L, Florenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih Ie M, Davidson B. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 2006; 449:31-9; PMID:16541284; http://dx. doi. org/ 10. 1007/s00428-005-0144-7
31. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 2005; 65:10139-44; PMID:16287995; http://dx. doi. org/ 10. 1158/0008-5472. CAN-05-0097
32. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol 2003; 4:815; PMID:12942076; http://dx. doi. org/10. 1038/ni0903-815
33. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111:4862-70; PMID:18334671; http://dx. doi. org/ 10. 1182/blood-2007-12-127662
34. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000; 287:1031; PMID:10669413; http://dx. doi. org/ 10. 1126/science. 287. 5455. 1031.
35. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/ NKG2A. Proc Natl Acad Sci U S A 1998; 95:5199-204; PMID:9560253; http://dx. doi. org/10. 1073/ pnas. 95. 9. 5199
36. Wei XH, Orr HT. Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol 1990; 29:131-42; PMID:2249951; http:// dx. doi. org/10. 1016/0198-8859(90)90076-2
37. Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F. Analysis of HLAE expression in human tumors. Immunogenetics 2003; 54:767-75; PMID:12618909
38. Hoare HL, Sullivan LC, Clements CS, Ely LK, Beddoe T, Henderson KN, Lin J, Reid HH, Brooks AG, Rossjohn J. Subtle changes in peptide conformation profoundly affect recognition of the non-classical MHC class I molecule HLA-E by the CD94-NKG2 natural killer cell receptors. J Mol Biol 2008; 377:1297-303; PMID:18339401; http://dx. doi. org/10. 1016/j. jmb. 2008. 01. 098
39. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391:795-9; PMID:9486650; http://dx. doi. org/ 10. 1038/35869
40. Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Soderstrom K, Levitskaya J et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 2002; 110:1515-23; PMID:12438449; http:// dx. doi. org/10. 1172/JCI0215564
41. Marchesi M, Andersson E, Villabona L, Seliger B, Lundqvist A, Kiessling R, Masucci GV. HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med 2013; 11:247; PMID:24093459; http://dx. doi. org/10. 1186/1479-5876-11-247
42. Pietra G, Romagnani C, Manzini C, Moretta L, Mingari MC. The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol 2010; 2010:907092; PMID:20634877; http://dx. doi. org/10. 1155/2010/907092
43. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV. Correlation of HLA-A02 * genotype and HLA class I antigen downregulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 2012; 61:1243-53; PMID:22258792; http://dx. doi. org/10. 1007/ s00262-012-1201-0
44. Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 2006; 103:145-50; PMID:16542716; http://dx. doi. org/10. 1016/j. ygyno. 2006. 02. 004
45. Park B, Lee S, Kim E, Chang S, Jin M, Ahn K. The truncated cytoplasmic tail of HLA-G serves a qualitycontrol function in post-ER compartments. Immunity 2001; 15:213-24; PMID:11520457; http://dx. doi. org/ 10. 1016/S1074-7613(01)00179-0
46. Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H, van Hall T. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc Natl Acad Sci 2011; 108:10656-61; PMID:3127933; http://dx. doi. org/10. 1073/pnas. 1100354108
47. Polakova K, Kuba D, Russ G. The 4H84 monoclonal antibody detecting beta2m free nonclassical HLA-G molecules also binds to free heavy chains of classical HLA class I antigens present on activated lymphocytes. Hum Immunol 2004; 65:157-62; PMID:14969770; http://dx. doi. org/10. 1016/j. humimm. 2003. 10. 005
48. Polakova K, Bennink JR, Yewdell JW, Bystricka M, Bandzuchova E, Russ G. Mild acid treatment induces cross-reactivity of 4H84 monoclonal antibody specific to nonclassical HLA-G antigen with classical HLA class I molecules. Hum Immunol 2003; 64:256-64; PMID:12559628; http://dx. doi. org/10. 1016/S0198-8859(02)00777-2
49. Kochan G, Escors D, Breckpot K, Guerrero-Setas D. Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology 2013; 2: e26491; PMID:24482746; http://dx. doi. org/10. 4161/ onci. 26491
50. Lin A, Chen HX, Zhu CC, Zhang X, Xu HH, Zhang JG, Wang Q, Zhou WJ, Yan WH. Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med 2010; 14:2162-71; PMID:19799650; http://dx. doi. org/ 10. 1111/j. 1582-4934. 2009. 00917. x
51. McCormick J, Whitley GS, Le Bouteiller P, Cartwright JE. Soluble HLA-G regulates motility and invasion of the trophoblast-derived cell line SGHPL-4. Hum Reprod 2009; 24:1339-45; PMID:19223288; http:// dx. doi. org/10. 1093/humrep/dep026
52. Morandi F, Airoldi I, Pistoia V. IL-27 driven upregulation of surface HLA-E expression on monocytes inhibits IFN-gamma release by autologous NK cells. J Immunol Res 2014; 2014:938561; PMID:24741633; http://dx. doi. org/10. 1155/2014/ 938561
53. Clements CS, Kjer-Nielsen L, Kostenko L, Hoare HL, Dunstone MA, Moses E, Freed K, Brooks AG, Rossjohn J, McCluskey J. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci U S A 2005; 102:3360-5; PMID:15718280; http://dx. doi. org/10. 1073/pnas. 0409676102
54. Menier C, Prevot S, Carosella ED, Rouas-Freiss N. Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology. Hum Immunol 2009; 70:1006-9; PMID:19660509; http://dx. doi. org/10. 1016/j. humimm. 2009. 07. 021
55. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003; 171:1918-26; PMID:12902494; http://dx. doi. org/10. 4049/ jimmunol. 171. 4. 1918
56. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT et al. HLA class I antigen processing machinery component expression and intratumoral TCell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008; 14:3372-9; PMID:18519766; http://dx. doi. org/10. 1158/1078-0432. CCR-07-4433